Brind.

Prothena announced advancements with Roche regarding prasinezumab, alongside potential milestone payments from Novo Nordisk and Bristol Myers Squibb.

2 reports, 1 independent Updated Aug 5

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Prothena announced advancements with Roche regarding prasinezumab, alongside potential milestone payments from Novo Nordisk and Bristol Myers Squibb.

Who's involved

What this event is mainly about

Hoffmann-La Roche Prothena (Ireland)

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
Prothena (Ireland)
company in Dublin, Ireland

Nothing else this week.

Related events

Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.Aug 6

Coverage

Newest first; wire copies grouped

Aug 5Business WireProthena Reports Second Quarter 2025 Financial Results and Business Highlights Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operati
Jul 5Unknown outlet